摘要
目的比较两种不同给药方式进行尘螨变应原特异性免疫治疗对缓解期哮喘患者的临床疗效和安全性。方法筛选40例缓解期尘螨过敏的哮喘患者,随机分为两组,分别给予尘螨变应原舌下含服(SLIT)和皮下注射(SCIT)脱敏治疗,总疗程为1年,观察两组的临床疗效和安全性。结果两组患者治疗前后吸入糖皮质激素日剂量、哮喘控制问卷(ACQ)、哮喘生命质量调查问卷(AQLQ)评分、尘螨皮肤试验反应度均得到改善(P<0.05),但改善程度组间比较无显著性差异(P>0.05)。两组患者哮喘得以控制的比例在治疗前后均有所增加(P<0.05),但组间无统计学差异(P>0.05)。肺功能指标、血清sIgE、嗜酸粒细胞百分比在治疗前后无明显变化(P>0.05)。SLIT组常见不良反应为局部刺激、胃肠道不适,SCIT组常见不良反应为皮疹、乏力和哮喘发作。结论尘螨变应原SLIT与SCIT特异性免疫治疗疗效相当,前者在依从性及安全性上具有更大优势。
Objective To evaluate the clinical efficacy and safety of specific immunotherapy for mite allergic bronchial asthma through two different administration routes.Methods Totally 40 patients with relieved mite allergic asthma were divided randomly into two groups.The two groups were treated with sublingual immunotherapy（SLIT） and subcutaneous immunotherapy（SCIT）,respectively,for one year.Then we recorded the clinical efficacy and safety indexes of the two groups.Results There were significant differences before and after immunotherapy in the percentage of controlled patients,dosage of inhaled corticosteroids,ACQ and AQLQ scores,and skin prick test in the two groups（P〈0.05）.The indexes above were all improved to different extents after immunotherapy,but there was no difference in the improved level between the two groups（P〉0.05）.Lung function,percentage of eosinophils and sIgE did no change significantly in the two groups after therapy（P〉0.05）.Common adverse reactions such as tongue swelling,prick,gastrointestinal discomfort and throat discomfort were observed in SLIT group,while asthma attack,rash and fatigue were found in SCIT group.Conclusion Sublingual immunotherapy and subcutaneous therapy have equivalent therapeutic effects in specific immunotherapy for mite allergen,and the former has a greater advantage in compliance and safety
出处
《西安交通大学学报（医学版）》
CAS
CSCD
北大核心
2011年第3期371-374,共4页
Journal of Xi’an Jiaotong University（Medical Sciences）
基金
陕西省科技攻关项目(2008K15-06(12))~~
关键词
尘螨
特异性免疫治疗
给药途径
mite
specific immunotherapy
administration route
